by Usha Govindarajulu | Mar 30, 2022 | Biostatistics, Blog, COVID-19, Epidemiology, Healtcare, Usha Govindarajulu
March 30, 2022 Latest research published in the Lancet shows diabetes onset was higher for those with post-acute sequelae or long-haul COVID-19 however these may be preliminary results. The results came from a cohort study which used databases from the United States...
by Usha Govindarajulu | Mar 16, 2022 | Biostatistics, Blog, COVID-19, Epidemiology, Healtcare, Usha Govindarajulu
March 15, 2022 In a recent article in The Scientist than appeared back in January, they mentioned using several pre-print articles which are cited for this article. In one of the pre-print articles by Adamson et al published on March 5 about a very recent small study...
by Usha Govindarajulu | Sep 1, 2021 | Biostatistics, Blog, Epidemiology, Healtcare, Usha Govindarajulu
Waning of efficacy and interpretation A lot of controversy has come up with the boosters for the COVID-19 vaccines and efficacy. The Israeli study on efficacy comparing people vaccinated last year to people vaccinated this year seemed to indicate the efficacy...
by Usha Govindarajulu | Aug 18, 2021 | Blog, Epidemiology, Healtcare, Usha Govindarajulu
Understanding percentages and efficacy August 18, 2021 Recently, there has been a lot of news about COVID-19 research tied to the studies conducted in Israel since they have such a high rate of vaccination and since they themselves have conducted several analyses...
by Usha Govindarajulu | Jul 9, 2021 | Biostatistics, Blog, Epidemiology, Healtcare, Professor, Usha Govindarajulu
Re-analyses on vaccine efficacy in COVID-19 research Much of the news these days focuses on vaccine efficacy rates being re-updated due to various new COVID-19 variants coming out often, originating in different countries, like delta (B.1.167.2) from India and lambda...
by Usha Govindarajulu | Mar 3, 2021 | Biostatistics, Blog, Epidemiology, New York, Professor, Usha Govindarajulu
As of right now, this is what we know about serious safety concerns raised about these COVID-19 vaccines: the mRNA vaccines, Pfizer© and Moderna©, the Johnson & Johnson©vaccine, and the Oxford/Astrazeneca© vaccine. These are the current vaccines with...
